About Us
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders, to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 17 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, four long-acting technologies, three oral antiviral treatments for COVID-19 and 12 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC). MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, and SDC.
Featured
mRNA Technology Transfer Hub Programme
12 April 2022
LAPaL
14 February 2022
Access to Medicines Tracker
02 March 2020
VaxPaL
08 June 2021
Discover MedsPaL
MedsPaL, MPP’s medicines patents and licences database, is a free resource that provides information on the intellectual property status of selected patented essential medicines in low- and middle-income countries.
MPP in Numbers
patent holders with MPP signed agreements
generic manufacturers and product developers have sublicences from MPP
For Everyone Everywhere
Discover where we helped and what we have achieved
Patent and licensing status: last updated on 11 May 2021. Disclaimer | Product availability data from MPP sublicensees: last updated in September 2022 (data as of 31 June 2022) | Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions
Impact Stories
How access to antiretrovirals is building the future
Key Publications
Twitter Feed
Esteban Burrone @eburrone
Wow! Already 6 years! It all started with an oversized excel sheet and developed into a huge database covering 140 essential meds. I particularly wish to thank @PascaleBoulet who conceptualized and managed it at the start, and Amina Maillard who has led it for the past 4 years. https://t.co/y6AdfTL03E
MedicinesPatentPool @MedsPatentPool
New #Job Opportunity 🚀 We're looking for a #Grants and #Operations Manager to ensure the efficient management of grants and #donor 🤝🏾 relations and support the delivery of the strategic implementation plan. 🗓️Deadline ➡️ 26 Oct 2022 💻 Apply ➡️ https://t.co/QGhtVNkIQW https://t.co/x6CDCbIiZz
Unitaid @UNITAID
The @MedsPatentPool has signed a voluntary licence agreement with Japanese pharmaceutical company, @SHIONOGI_JP, to enable generic companies to produce its COVID-19 antiviral treatment pill candidate, provided it gets regulatory approval. Learn more: https://t.co/j4xBDKHrvr https://t.co/Df8ooxOg1B
Health Policy Watch - Global Health News Reporting @HealthPolicyW
.@MedsPatentPool already has voluntary licenses for the two antivirals recommended by the @WHO with @MSDInvents for molnupiravir and with @pfizer for Paxlovid to help make generic versions of those antiviral drugs. 💊💊 @CharlieGore | @SHIONOGI_JP https://t.co/URByjXsN3L
MedicinesPatentPool @MedsPatentPool
🥳Today, we celebrate 6⃣ years of the #patents & #licences database, #MedsPaL❗️ 🗣️ It provides information on the patent and licensing status of selected #HIV, #hepatitisC, #tuberculosis & other patented essential 💊medicines in LMICs. Discover More 👉🏾 https://t.co/P7g9CFoeL2 https://t.co/wgL4eoqBV2
